Evidence map›Paper›PMID 22411188›Full record

ArticleDalton transactions (Cambridge, England : 2003)2012

Investigating chelating sulfonamides and their use in metalloproteinase inhibitors.

Alisa Tanakit, Matthieu Rouffet, David P Martin, Seth M Cohen

Abstract read
In one paragraph

Article in Dalton transactions (Cambridge, England : 2003), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Decoding the Implications of Zinc in the Development and Therapy of Leukemia.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  3. Network Pharmacology, Molecular Docking andCurrent computer-aided drug design · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Alisa TanakitDepartment of Chemistry and Biochemistry, University of California, San Diego, La Jolla, California 92093-0358, USA.
Matthieu Rouffet
David P Martin
Seth M Cohen
University of California, San Diego · US

Funding

Insight and Optimization of Metalloprotein InhibitorsR01GM098435 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI THEODORAKIS, EMMANUEL A · 2011 to 2018
$2.2M
New Strategies and Screening Methods for Metalloproteinase InhibitionR21HL094571 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI COHEN, SETH M · 2009 to 2010
$373k
NHLBI NIH HHS R21 HL094571NIGMS NIH HHS R01 GM098435
6 · The paper itself

Abstract

Matrix metalloproteinase inhibitors (MMPi) utilize zinc-binding groups (ZBGs) to chelate the catalytic Zn(II) ion resulting in enzyme inhibition. Adapting findings from the literature of Zn(II) ion sensors, we previously reported chelating sulfonamide inhibitors of MMP-2, some of which showed excellent selectivity over other gelatinases (MMP-9). Herein, we greatly expand our investigation of chelating sulfonamides as MMP inhibitors (MMPi) with the synthesis and screening of several new libraries consisting of 2-phenyl-7-sulfonamidobenzimidazole, 2-phenyl-7-sulfonamidobenzoxazole, 7-sulfonamidobenzimidazole, 7-sulfonamidobenzoxazole, and 2-(2-sulfonamidophenyl)-quinoline ZBG derivatives. A novel microwave irradiation synthetic procedure was utilized to rapidly and efficiently prepare these molecules. To better understand the coordination chemistry underlying these ZBGs, crystal structures of representative molecules with several first row transition metals were determined and differences in coordination preferences were considered. Surprisingly, only compounds with the 2-phenyl-7-sulfonamidobenzimidazole ZBG showed inhibition of MMP-2, suggesting that the specific structure of the ZBG can have a pronounced effect of inhibitory activity.

Indexed as

Matrix Metalloproteinase InhibitorsChelating AgentsHumansLigandsModels, MolecularMolecular ConformationProtease InhibitorsSulfonamidesZincChelating AgentsLigandsMatrix Metalloproteinase InhibitorsProtease InhibitorsSulfonamidesZinc

Identifiers

PMID22411188
PMCPMC3685695
OpenAlexW1975266034

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.